Skip to main content

Dermatology

Guselkumab Treats Axial Disease in Psoriatic Arthritis

Sep 23, 2021

Pooled analysis of the DISCOVER-1 and DISCOVER-2 trials have shown that guselkumab, an IL-23 inhibitor, was effective and safe in psoriatic arthritis (PsA) patients with axial involvement and imaging-confirmed sacroiliitis.

Read Article

IL-6 Inhibition in Refractory Systemic Sclerosis

Sep 22, 2021

A small, single-center cohort analysis of difficult, refractory systemic sclerosis (SSc) patients showed that treatment with tocilizumab (TCZ), an interleukin-6 inhibitor, resulted in significant improvement in joint and skin involvement, regardless of SSc disease duration or subtype. 

Read Article
ICYMI: https://t.co/wM1iRxtHvk The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc) and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization. https://t.co/A8dfCksp3b
Dr. John Cush @RheumNow( View Tweet )
Sep 12, 2021

RheumNow Podcast – High Science and Future Treatments (9.10.2021)

Sep 10, 2021

This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.

Read Article

Risk Factors Associated with Systemic Sclerosis Hospitalization

Sep 09, 2021

A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease.



Record review of 95 SSc patients from a single-centre cohort seen between 2010 and 2020 found that over half (53

Read Article

Diagnostic Delay in Half of Psoriatic Arthritis Patients

Sep 07, 2021

 A Mayo Clinic/ Olmsted County study of psoriatic arthritis (PsA) patients has shown that more than half (55%) of PsA patients had a diagnostic delay of > 2 years, and that this delay has not improved over time.



A retrospective, population-based cohort examined incident adult PsA

Read Article

Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors

Sep 02, 2021

Dr. Jack Cush is joined by Drs. Roy Fleischmann (Dallas), Allan Gibofsky (NYC), and Artie Kavanaugh (San Diego) to discuss the 9/2/21 FDA Drug Safety Communication regarding the cardiovascular and cancer risks arising from the Pfizer 1133 (ORAL Surveillance) tofacitinib study, but also applied

Read Article

FDA: New Cardiac and Cancer Warnings for All JAK Inhibitors

Sep 01, 2021

Today, Sept.1st, the FDA announced its decision regarding tofacitinib's safety concerns from the Oral Surveillance study - handing down warnings for not only Pfizer's JAK inhibitor, but also for other marketed JAK inhibitors from AbbVie and Eli Lilly & Co.

These safety concerns arise from

Read Article
Data from 4 parallel case-control studies within The Health Improvement Network looked at risk factors for developing PsA, psoriasis, RA, and AS showed both shared and differentiating risk factors, but statin use was protective in all 4 conditions. https://t.co/qXlpKVwwWg https://t.co/08jF5jPEH0
Dr. John Cush @RheumNow( View Tweet )
Sep 01, 2021

TNF Inhibitor Induced IgA Vasculitis in IBD

Aug 31, 2021

A new descriptive series shows an uncommon association between IgA vasculitis (IgAV) and inflammatory bowel diseases (IBD), with most cases interestingly arising after  or during anti-TNF-α therapy.



A retrospectively analysis of the GETAID and FVSG networks identified, 43 patients

Read Article

Predictors of Inflammatory Arthritis

Aug 31, 2021

Data from 4 parallel case-control studies within The Health Improvement Network looked at risk factors for developing psoriatic arthritis (PsA), psoriasis, rheumatoid arthritis (RA), and ankylosing spondylitis (AS) showed both shared and differentiating risk factors, but statin use was

Read Article
In case you missed it: Biologic Therapy of Psoriasis May Prevent Psoriatic Arthritis Another retrospective cohort study has shown that biologic treatment of psoriasis may reduce the subsequent incidence of psoriatic arthritis (PsA). https://t.co/2YbLBsFedv https://t.co/OYMJ6Y54UF
Dr. John Cush @RheumNow( View Tweet )
Aug 28, 2021

RheumNow Podcast – COVID Marching Amidst the Madness (8.27.2021)

Aug 26, 2021

We have a lot of news, information and approvals to review and discuss, though I need to begin with what's weighing heavily on my mind. After, we'll dive into what we learned this week.

Read Article
European Commission approves upadacitinib (Rinvoq)-first JAK Inhibitor for use in adults & adolescents with Moderate to Severe Atopic Dermatitis. UPA is approved for atopic dermatitis in other nations, Russia, Saudi Arabia; pending review in US https://t.co/hiPkJoJCex

Dr. John Cush @RheumNow( View Tweet )

Aug 25, 2021
European Commission has approved bimekizumab (Bimzelx) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis. Bimekizumab is a dual IL-17 inhibitor (IL-17A and IL-17F). https://t.co/viRNbx2cbt

Dr. John Cush @RheumNow( View Tweet )

Aug 24, 2021

Biologic Therapy of Psoriasis May Prevent Psoriatic Arthritis

Aug 24, 2021

Another retrospective cohort study has shown that biologic treatment of psoriasis may reduce the subsequent incidence of psoriatic arthritis (PsA).



Analysis of electronic medical records of a large HMO identfied psoriasis patients who had received treatment for psoriasis (but were

Read Article
Psoriasis Prevalence in adults in the United States is 3.0%, indicating that more than 7.5 million adults 20 years or older have psoriasis. Most common in non-Hispanic White individuals; prevalence has not significantly changed since 2003. https://t.co/3yrlPu1GGi

Dr. John Cush @RheumNow( View Tweet )

Aug 24, 2021

Tocilizumab in Refractory Skin and Joint Scleroderma

Aug 18, 2021

The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc)  and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization.



TCZ is currently FDA approved for use in SSc

Read Article

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

Aug 13, 2021

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.




  1. In a head to head trial Upadacitinib was superior to Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. 24wk DBRCT, 924 pts given either UPA 30/d vsDUP 300 EOW. ESI75 response@

Read Article
In a head to head trial Upadacitinib was superior to Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. 24wk DBRCT, 924 pts given either UPA 30/d vsDUP 300 EOW. ESI75 response@wk16, UPA 71% vs DUP 61% https://t.co/5cOoosKyao

Dr. John Cush @RheumNow( View Tweet )

Aug 08, 2021

Skin Involvement with HMGCR Necrotizing Myositis

Aug 04, 2021

The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, moreso than previously reported.



Anti-3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies have been linked to the immune-mediated

Read Article

FDA Approves Anifrolumab in SLE

Aug 02, 2021

AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.  



Saphnelo the 

Read Article
RheumNow Podcast – Psoriatic Arthritis Without Psoriasis Download wherever you get your podcasts! https://t.co/Ra5f7507XT https://t.co/5WqPCgGVpr
Dr. John Cush @RheumNow( View Tweet )
Jul 31, 2021

RheumNow Podcast – Psoriatic Arthritis Without Psoriasis (7.30.2021)

Jul 30, 2021

How much psoriasis do you need to have in order to have psoriatic arthritis? This plus a review of rheumatology and COVID news from the past week on RheumNow.com.

Read Article

Shingles Risk with JAK Inhibitors and Other Biologics

Jul 29, 2021

Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.



RA patients from the German RABBIT register were prospectively enrolled (2007 - 2020)

Read Article
×